Cardioprotective Effect of Atorvastatin in Lymphoma Patients Receiving CHOP/R-CHOP regimen, A Randomized Control Trial

Phase 3

Recruiting

• Conditions: CHOP; RCHOP; lymphoma; atorvastatin; Aggressive non- Hodgkin' s lymphoma requiring CHOP/R- CHOP treatment; cardiotoxicity; chemotherapy

• Registration Number: TCTR20180202004
• Lead Sponsor: Faculty of Medicine Chiang Mai University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-02-02
• Study Completion: 2019-05-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

1. Adult patients 18-70 years old, who recently diagnosed with lymphoma and assigned to receive CHOP and R-CHOP regimens
2. Normal sinus rhythm with baseline LVEF>50%
3. ECOG performance status 0-2

Exclusion Criteria

1. Pre-existing heart failure, coronary artery disease, structural heart disease
2. Prior mediastinal radiotherapy and ongoing or expected need to be treated with mediastinal radiotherapy
3. Liver impairment, defined as AST or ALT >3 times of upper limit of normal, TB >2 times of upper limit of normal; not considering form involvement of lymphoma
4. Alcoholism, alcohol dependent
5. Ongoing or expected need to be treated with statin, ACEIs, ARBs or beta-blocker from other conditions
Allergic to statin

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
pro BNP baseline, every cycle of chemotherapy blood exam

Secondary Outcome Measures

Name	Time	Method
cardiac markers baseline, every cycle of chemotherapy blood exam,echocardiogram baseline and at the end of chemotherapy echocardiogram, global longitudinal strain,oxidative stress marker baseline, every cycle of chemotherapy blood exam